Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRAS(G12D) mutated pancreatic cancer in vivo model

Pancreatic cancer (PC) has a very low survival rate mainly due to late diagnosis and refractoriness to therapies. The latter also cause adverse effects negatively affecting the patients’ quality of life, often requiring dose reduction or discontinuation of scheduled treatments, compromising the chan...

Descripción completa

Detalles Bibliográficos
Autores principales: Panebianco, Concetta, Pisati, Federica, Villani, Annacandida, Andolfo, Annapaola, Ulaszewska, Marynka, Bellini, Edoardo, Ferro, Carmelapia, Lombardi, Renato, Orsenigo, Fabrizio, Latiano, Tiziana Pia, Belmonte, Beatrice, Tripodo, Claudio, Perri, Francesco, Pazienza, Valerio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076501/
https://www.ncbi.nlm.nih.gov/pubmed/37019893
http://dx.doi.org/10.1038/s41420-023-01397-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076501/
https://www.ncbi.nlm.nih.gov/pubmed/37019893
http://dx.doi.org/10.1038/s41420-023-01397-y

Ejemplares similares